Judith Segall - Net Worth and Insider Trading

Judith Segall Net Worth

The estimated net worth of Judith Segall is at least $493,770 dollars as of 2024-11-13. Judith Segall is the Vice President & Secretary of Lineage Cell Therapeutics Inc and owns about 520,415 shares of Lineage Cell Therapeutics Inc (LCTX) stock worth over $493,770. Details can be seen in Judith Segall's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Judith Segall has not made any transactions after 2010-11-23 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Judith Segall

Judith Segall Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Judith Segall owns 4 companies in total, including AgeX Therapeutics Inc (AGE) , Lineage Cell Therapeutics Inc (LCTX) , and OncoCyte Corp (OCX) among others .

Click here to see the complete history of Judith Segall’s form 4 insider trades.

Insider Ownership Summary of Judith Segall

Ticker	Comapny	Transaction Date	Type of Owner
AGE	AgeX Therapeutics Inc	2018-11-27	Corporate Secretary
LCTX	Lineage Cell Therapeutics Inc	2010-11-23	director & VP;Member & Office of President
OCX	OncoCyte Corp	2015-12-30	Corporate Secretary
		2015-02-13	director & Corporate Secretary

Judith Segall Latest Holdings Summary

Judith Segall currently owns a total of 1 stock. Judith Segall owns 520,415 shares of Lineage Cell Therapeutics Inc (LCTX) as of November 23, 2010, with a value of $493,770.

Latest Holdings of Judith Segall

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
LCTX	Lineage Cell Therapeutics Inc	2010-11-23	520,415	0.95	493,770

Holding Weightings of Judith Segall

Judith Segall Form 4 Trading Tracker

According to the SEC Form 4 filings, Judith Segall has made a total of 0 transactions in Lineage Cell Therapeutics Inc (LCTX) over the past 5 years. The most-recent trade in Lineage Cell Therapeutics Inc is the sale of 27,128 shares on November 23, 2010, which brought Judith Segall around $204,003.

Insider Trading History of Judith Segall

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Judith Segall Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Judith Segall Ownership Network

Ownership Network List of Judith Segall

No Data

Ownership Network Relation of Judith Segall

Judith Segall Owned Company Details

What does AgeX Therapeutics Inc do?

Who are the key executives at AgeX Therapeutics Inc?

Judith Segall is the Corporate Secretary of AgeX Therapeutics Inc. Other key executives at AgeX Therapeutics Inc include director & 10 percent owner Juvenescence Us Corp. , Chief Financial Officer Park Andrea Eun Jae , and director & Chief Executive Officer Michael D West .

AgeX Therapeutics Inc (AGE) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of AgeX Therapeutics Inc (AGE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of AgeX Therapeutics Inc (AGE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

AgeX Therapeutics Inc (AGE)'s detailed insider trading history can be found in Insider Trading Tracker table.

AgeX Therapeutics Inc Insider Transactions

No Available Data

What does Lineage Cell Therapeutics Inc do?

Who are the key executives at Lineage Cell Therapeutics Inc?

Judith Segall is the director & VP;Member & Office of President of Lineage Cell Therapeutics Inc. Other key executives at Lineage Cell Therapeutics Inc include Chief Financial Officer Jill Ann Howe , director & President and CEO Brian M Culley , and 10 percent owner Broadwood Partners Lp .

Lineage Cell Therapeutics Inc (LCTX) Insider Trades Summary

Over the past 18 months, Judith Segall made no insider transaction in Lineage Cell Therapeutics Inc (LCTX). Other recent insider transactions involving Lineage Cell Therapeutics Inc (LCTX) include a net purchase of 6,730,770 shares made by Broadwood Partners Lp , a net purchase of 96,155 shares made by Don M Bailey , and a net purchase of 10,500 shares made by Jill Ann Howe .

In summary, during the past 3 months, insiders sold 0 shares of Lineage Cell Therapeutics Inc (LCTX) in total and bought 10,500 shares, with a net purchase of 10,500 shares. During the past 18 months, 0 shares of Lineage Cell Therapeutics Inc (LCTX) were sold and 6,857,425 shares were bought by its insiders, resulting in a net purchase of 6,857,425 shares.

Lineage Cell Therapeutics Inc (LCTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Lineage Cell Therapeutics Inc Insider Transactions

No Available Data

What does OncoCyte Corp do?

Who are the key executives at OncoCyte Corp?

Judith Segall is the Corporate Secretary of OncoCyte Corp. Other key executives at OncoCyte Corp include 10 percent owner Broadwood Partners Lp , Interim CEO Josh Riggs , and other: Former Director John Peter Gutfreund .

OncoCyte Corp (OCX) Insider Trades Summary

Over the past 18 months, Judith Segall made no insider transaction in OncoCyte Corp (OCX). Other recent insider transactions involving OncoCyte Corp (OCX) include a net purchase of 3,735,339 shares made by Broadwood Partners Lp , a net purchase of 33,898 shares made by Andrew Arno , and a net purchase of 33,670 shares made by .

In summary, during the past 3 months, insiders sold 0 shares of OncoCyte Corp (OCX) in total and bought 1,349,009 shares, with a net purchase of 1,349,009 shares. During the past 18 months, 0 shares of OncoCyte Corp (OCX) were sold and 3,807,797 shares were bought by its insiders, resulting in a net purchase of 3,807,797 shares.

OncoCyte Corp (OCX)'s detailed insider trading history can be found in Insider Trading Tracker table.

OncoCyte Corp Insider Transactions

No Available Data

What does Asterias Biotherapeutics Inc do?

Who are the key executives at Asterias Biotherapeutics Inc?

Judith Segall is the director & Corporate Secretary of Asterias Biotherapeutics Inc. Other key executives at Asterias Biotherapeutics Inc include other: See Remarks Below Neal C Bradsher , other: See Remarks Below Broadwood Partners Lp , and other: See Remarks Below Broadwood Capital Inc .

Asterias Biotherapeutics Inc (AST) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Asterias Biotherapeutics Inc (AST) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Asterias Biotherapeutics Inc (AST) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Asterias Biotherapeutics Inc (AST)'s detailed insider trading history can be found in Insider Trading Tracker table.

Asterias Biotherapeutics Inc Insider Transactions

No Available Data

Judith Segall Mailing Address

Above is the net worth, insider trading, and ownership report for Judith Segall. You might contact Judith Segall via mailing address: 1010 Atlantic Avenue, Suite 102, Alameda Ca 94501.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.